May 26, 2026 11:02AM
May 26, 2026 11:01AM
May 18, 2026 08:02AM
May 18, 2026 08:00AM
May 4, 2026 04:05PM
Mar 2, 2026 06:32AM
Mar 2, 2026 06:30AM Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
May 25, 2023 05:00PM
May 10, 2023 07:00AM
Mar 30, 2023 07:03AM
Mar 30, 2023 07:00AM
Mar 7, 2023 07:00AM
Jan 9, 2023 08:33AM
Jan 9, 2023 08:30AM Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023
Nov 29, 2022 09:03AM
Nov 29, 2022 09:01AM
Nov 28, 2022 04:01PM
Nov 28, 2022 04:01PM
Nov 14, 2022 07:00AM
Nov 7, 2022 08:00AM
Sep 21, 2022 08:32AM Alaunos Therapeutics (TCRT) Highlights Data from TCR-T Library Phase 1/2 Trial
Sep 21, 2022 08:30AM
Sep 6, 2022 08:00AM
Aug 24, 2022 03:00PM
Aug 15, 2022 07:00AM
Aug 4, 2022 05:00PM
Jun 27, 2022 08:00AM
May 26, 2022 05:01PM Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting
May 16, 2022 07:30AM
May 2, 2022 04:31PM
May 2, 2022 08:30AM
Mar 30, 2022 07:30AM

322,093 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All